BACKGROUND: The family of G-protein-coupled receptors (GPCRs) serves as the target for almost a third of currently marketed drugs and provides the predominant mechanism through which extracellular factors transmit signals to the cell. GPCRs have been proved to be good therapeutic targets for metabolic disorders. In recent years, a number of companies have been actively involved in the discovery of small-molecule modulators of the GPR40 (FFA1) receptor. However, to date, no critical, comprehensive review on small-molecule modulators of GPR40 (FFA1) has been published. OBJECTIVE: To review the discovery and development of small-molecule GPR40 (FFA1) agonists/antagonists by different research groups and to classify them based on the key structural features. METHOD: Systematic search, analysis, and summary of the publication and patent literature for small-molecule modulators of the GPR40 (FFA1) receptor to June 2008. The patent information for this review is drawn from the Integrity Prous, Scifinder, Esp@cenet, and freepatentonline.com databases. CONCLUSION: The para-substituted phenyl propionic acid scaffold has emerged as a common structural motif found in many GPR40 (FFA1) agonists, and compounds having an aromatic ring and a group capable of releasing a cation have exhibited excellent GPR40 (FFA1) agonistic activity. Several small-molecule agonists of GPR40 (FFA1) have been discovered, which offer a great promise in the treatment of type 2 diabetes.
BACKGROUND: The family of G-protein-coupled receptors (GPCRs) serves as the target for almost a third of currently marketed drugs and provides the predominant mechanism through which extracellular factors transmit signals to the cell. GPCRs have been proved to be good therapeutic targets for metabolic disorders. In recent years, a number of companies have been actively involved in the discovery of small-molecule modulators of the GPR40 (FFA1) receptor. However, to date, no critical, comprehensive review on small-molecule modulators of GPR40 (FFA1) has been published. OBJECTIVE: To review the discovery and development of small-molecule GPR40 (FFA1) agonists/antagonists by different research groups and to classify them based on the key structural features. METHOD: Systematic search, analysis, and summary of the publication and patent literature for small-molecule modulators of the GPR40 (FFA1) receptor to June 2008. The patent information for this review is drawn from the Integrity Prous, Scifinder, Esp@cenet, and freepatentonline.com databases. CONCLUSION: The para-substituted phenyl propionic acid scaffold has emerged as a common structural motif found in many GPR40 (FFA1) agonists, and compounds having an aromatic ring and a group capable of releasing a cation have exhibited excellent GPR40 (FFA1) agonistic activity. Several small-molecule agonists of GPR40 (FFA1) have been discovered, which offer a great promise in the treatment of type 2 diabetes.
Authors: Melkam Kebede; Mourad Ferdaoussi; Arturo Mancini; Thierry Alquier; Rohit N Kulkarni; Michael D Walker; Vincent Poitout Journal: Proc Natl Acad Sci U S A Date: 2012-01-30 Impact factor: 11.205
Authors: R G Pertwee; A C Howlett; M E Abood; S P H Alexander; V Di Marzo; M R Elphick; P J Greasley; H S Hansen; G Kunos; K Mackie; R Mechoulam; R A Ross Journal: Pharmacol Rev Date: 2010-12 Impact factor: 25.468
Authors: Sean P Brown; Paul Dransfield; Marc Vimolratana; Liusheng Zhu; Jian Luo; Jane Zhang; XianYun Jiao; Vatee Pattaropong; Simon Wong; Run Zhuang; Gayathri Swaminath; Jonathan B Houze; Daniel C-H Lin Journal: ACS Med Chem Lett Date: 2018-06-06 Impact factor: 4.345
Authors: Xiaohui Du; Paul J Dransfield; Daniel C-H Lin; Simon Wong; Yingcai Wang; Zhongyu Wang; Todd Kohn; Ming Yu; Sean P Brown; Marc Vimolratana; Liusheng Zhu; An-Rong Li; Yongli Su; Xianyun Jiao; Jiwen Jim Liu; Gayathri Swaminath; Thanhvien Tran; Jian Luo; Run Zhuang; Jane Zhang; Qi Guo; Frank Li; Richard Connors; Julio C Medina; Jonathan B Houze Journal: ACS Med Chem Lett Date: 2014-02-03 Impact factor: 4.345
Authors: Sean P Brown; Paul J Dransfield; Marc Vimolratana; XianYun Jiao; Liusheng Zhu; Vatee Pattaropong; Ying Sun; Jinqian Liu; Jian Luo; Jane Zhang; Simon Wong; Run Zhuang; Qi Guo; Frank Li; Julio C Medina; Gayathri Swaminath; Daniel C-H Lin; Jonathan B Houze Journal: ACS Med Chem Lett Date: 2012-08-15 Impact factor: 4.345